tailieunhanh - báo cáo hóa học:" Effectiveness and Safety of Generic Fixed-Dose Combination of Tenofovir/Emtricitabine/Efavirenz in HIV-1-Infected Patients in Western India"

Tuyển tập các báo cáo nghiên cứu về hóa học được đăng trên tạp chí sinh học quốc tế đề tài : Effectiveness and Safety of Generic Fixed-Dose Combination of Tenofovir/Emtricitabine/Efavirenz in HIV-1-Infected Patients in Western India | Open Access Journal of the International AIDS BioMed Central Society Research article Effectiveness and Safety of Generic Fixed-Dose Combination of Tenofovir Emtricitabine Efavirenz in HIV-1-Infected Patients in Western India Sanjay Pujari Ameet Dravid Nikhil Gupte Kedar Joshix and Vivek Bele Address Institute of Infectious Diseases Kumar Business Court Pune India Email Sanjay Pujari - sanjaypujari@ Corresponding author Published 20 August 2008 Journal of the International AIDS Society 2008 10 196 This article is available from http content l0 8 l96 Abstract__ Objective To assess effectiveness and safety of a generic fixed-dose combination of tenofovir TDF emtricitabine FTC efavirenz EFV among HIV-1-infected patients in Western India. Methods Antiretroviral ARV -naive and experienced thymidine analog nucleoside reverse transcriptase inhibitor tNRTI replaced by TDF patients were started on a regimen of l TDF FTC EFV pill once a day. They were followed clinically on a periodic basis and viral loads and CD4 counts were measured at 6 and l2 months. Creatinine clearance was calculated at baseline and at 6 months and or as clinically indicated. Effectiveness was defined as not having to discontinue the regimen due to failure or toxicity. Results One hundred forty-one patients who started TDF FTC EFV before lJune 2007 were eligible. Of these 130 and 44 had 6- and l2-months follow-up respectively. Thirty-five percent of the patients were ARV-naive. Eleven patients discontinued treatment 4 for virologic failure l for grade 34 central nervous system disturbances 4 for grade 34 renal toxicity and 2 for cost . Ninety-six percent of patients were virologically suppressed at 6 months. Frequency of TDF-associated grade 34 renal toxicity was however 3 of these patients had comorbid conditions associated with renal dysfunction. Conclusion A fixed-dose .